MetLife Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

MetLife Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12,682	Closed	-$1.3M	–	3031
2023 Q2	$1.3M	Sell	12,682 -115	-0.9%	-$12.1K	0.01%	1129
2023 Q1	$1.4M	Buy	12,797 +30	+0.2%	+$3.32K	0.01%	1059
2022 Q4	$1.45M	Sell	12,767 -514	-4%	-$42.7K	0.01%	1026
2022 Q3	$822K	Buy	13,281 +1	+0%	+$70	0.01%	1291
2022 Q2	$1.06M	Buy	13,280 +7,091	+115%	+$672K	0.01%	1176
2022 Q1	$651K	Buy	+6,189	New	+$603K	﹤0.01%	1614
2019 Q3	–	Sell	-78,412	Closed	-$1.89M	–	2475
2019 Q2	$1.89M	Hold	78,412	–	–	0.02%	843
2019 Q1	$2.07M	Buy	78,412 +4,806	+7%	+$114K	0.02%	807
2018 Q4	$1.44M	Hold	73,606	–	–	0.02%	897
2018 Q3	$1.44M	Buy	+73,606	New	+$1.4M	0.01%	988

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MetLife Investment Management's HZNP Position: Q3 2023 in Review

MetLife Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 12,682 shares — an estimated $1.3M sold.

MetLife Investment Management first reported a position in HZNP in Q3 2018 and held it in 10 quarters. The position peaked at $2.07M in Q1 2019. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

MetLife Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
MetLife Investment Management sold 12,682 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $1.3M.
MetLife Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and held it in 10 quarters.
MetLife Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.07M in Q1 2019.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.